NCT04992013View on ClinicalTrials.gov

Niraparib in Tumors Metastatic to the CNS

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

June 1, 2027

Conditions

Metastatic CancerCentral Nervous System Cancer

Interventions

DRUG

Niraparib

Capsule taken by mouth

Trial Locations (1)

02114

Massachusetts General Hospital Cancer Center, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Massachusetts General Hospital

OTHER